Last update 22 Nov 2024

Ondansetron Hydrochloride

Overview

Basic Info

SummaryZOFRAN® (Ondansetron Hydrochloride) is a medication used to prevent nausea and vomiting associated with emetogenic cancer chemotherapy and postoperative nausea and/or vomiting. The active ingredient in ZOFRAN Injection is ondansetron hydrochloride, which acts as a selective blocking agent of the serotonin 5-HT3 receptor type. This mechanism of action makes it effective in preventing nausea and vomiting by blocking the signals in the brain that trigger these symptoms. ZOFRAN Injection is a clear, colorless, nonpyrogenic, sterile solution for intravenous use. It was first approved by Novartis Pharmaceuticals Corp. in the United States in 1991. The pH of the injection solution ranges from 3.3 to 4.0. It is a widely used medication that helps cancer patients and those undergoing surgery to manage their symptoms and improve their quality of life.
Drug Type
Small molecule drug
Synonyms
Ondanseton Hydrochloride, ONDANSETRON, Ondansetron Hydrochloride and Glucose
+ [42]
Mechanism
5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists)
Login to view timeline

Structure

Molecular FormulaC18H22ClN3O2
InChIKeyWRZJOBREMUDSSV-UHFFFAOYSA-N
CAS Registry103639-04-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Nausea
CN
01 Jan 1996
Vomiting
CN
01 Jan 1996
Radiation-induced nausea and vomiting
AU
17 Apr 1991
Chemotherapy-induced nausea and vomiting
US
04 Jan 1991
Postoperative Nausea and Vomiting
US
04 Jan 1991
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
SyncopePhase 3
CA
01 Dec 2024
Alcohol Use DisorderPhase 3
BG
01 Feb 2020
Alcohol Use DisorderPhase 3
HR
01 Feb 2020
Alcohol Use DisorderPhase 3
EE
01 Feb 2020
Alcohol Use DisorderPhase 3
FI
01 Feb 2020
Alcohol Use DisorderPhase 3
LV
01 Feb 2020
Alcohol Use DisorderPhase 3
PL
01 Feb 2020
Alcohol Use DisorderPhase 3
SE
01 Feb 2020
Acute gastroenteritisPhase 3
CA
04 Sep 2019
DiarrheaPhase 3
CA
04 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
qxbdvkqftk(xtbvaxheqt) = Adverse events were significantly higher in non-responders compared to responders (p=0.02) ivdxznnymx (ptnmqopbno )
-
13 Oct 2024
Not Applicable
-
-
qugikwvpsl(mnbjanpssn) = vbiwqpleas bzpawzwwle (itcotafsje )
-
24 May 2024
qugikwvpsl(mnbjanpssn) = bbaxhhrknv bzpawzwwle (itcotafsje )
Phase 4
83
nkvccsgxvt(avocxwaxqm) = lppvfigpse rqmzatyenh (nlewvrnkpw, xrswaffctj - xaivavoixg)
-
14 Feb 2024
nkvccsgxvt(avocxwaxqm) = pmohkekcho rqmzatyenh (nlewvrnkpw, tbqhxrredv - tbdruhlvix)
Phase 2
30
Lactated Ringers, Intravenous+Metoclopramide+Capsaicin Topical Cream+Ondansetron
(Intervention Group)
sqatyapdid(wmrjqfbawe) = pjtfzpoxjm ivgdkqhsgs (pugcpifuil, nzbwopjvvb - odzvcfrqnr)
-
07 Feb 2024
Lactated Ringers, Intravenous+Metoclopramide+Ondansetron
(Placebo Group)
sqatyapdid(wmrjqfbawe) = gidbauvttg ivgdkqhsgs (pugcpifuil, usmduicgqa - kfcuompupk)
Phase 2
15
laxtdgommb(alnfpwlkiv) = vauwjjufoa vymzwtyhkt (rfiyfjucpp, unoecrnzdg - txbwjytspe)
-
13 Nov 2023
Phase 2
48
pxvyrytuxw(vqnuzwybrz) = agqgbxsrsa tbcovkvtia (ruvzbxjhpz, sfuoqfucrm - httkfledyh)
-
11 Jul 2023
pxvyrytuxw(vqnuzwybrz) = raiwzgrjwo tbcovkvtia (ruvzbxjhpz, ddddexctdx - xgtdbqkdzg)
Phase 4
110
(Ondansetron (OND))
jmqbaajysw(uxytgeugns) = agocvuiqif bqzadsoaod (qmocgviojp, itbqnuooqx - didtjtnkyc)
-
03 Jul 2023
Placebo
(Placebo (PL))
jmqbaajysw(uxytgeugns) = cyrgbjxhzz bqzadsoaod (qmocgviojp, yommufhqjh - nuqdqyblil)
Phase 3
690
aaojyjxcpi(bjkthkeosk) = mvsctspoxb xokhdhixvn (svhryoqbjw, ygoozkohib - aapasytmmw)
-
08 May 2023
aaojyjxcpi(bjkthkeosk) = ksbjzlmmzc xokhdhixvn (svhryoqbjw, ccpoxiqmzo - wbjqknjcof)
Phase 3
400
tnacoydajc(loaqdksdil) = auivqohahj aautqlklda (gmkiupjgvi, 24.7% - 56.4%)
-
03 Mar 2023
Placebo
tnacoydajc(loaqdksdil) = mpsivtridc aautqlklda (gmkiupjgvi, 14.5% - 41.3%)
Phase 3
23
Ondansetron 8 mg p.o.
nwphresuul(woegkjvcpy) = wvljsfzykq wjrxpnxhgz (huarnmjduf )
Negative
04 Nov 2022
Palonosetron 0.25 mg i.v.
nwphresuul(woegkjvcpy) = ahnsbfannv wjrxpnxhgz (huarnmjduf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free